CA Patent

CA2753754C — Methods for treating schizophrenia

Assigned to Individual · Expires 2015-06-09 · 11y expired

What this patent protects

Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl} carbonylmethyl)ureido]phenyl}prop…

USPTO Abstract

Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl} carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.

Drugs covered by this patent

Patent Metadata

Patent number
CA2753754C
Jurisdiction
CA
Classification
—
Expires
2015-06-09
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.